Shares of Mirati Therapeutics (NASDAQ: MRTX), a high-flying biotech focused on cancer, plunged 16% as of 11:35 a.m. on Monday. The drop is a response to the release of clinical data from a phase 2 trial that failed to impress.Mirati presented data from its ongoing phase 2 trial that is testing its compound sitravatinib in combination with Bristol-Myers Squibb's (NYSE: BMY) blockbuster drug Opdivo as a possible treatment for lung cancer.Here's an overview of the key takeaways from the data:Continue reading